期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 22, 页码 -出版社
MDPI
DOI: 10.3390/ijms232213794
关键词
pluripotent stem cells; embryonic stem cells; induced pluripotent stem cell; clinical trials; retinal pigment epithelial cells; age-related macular degeneration; cell transplantation
资金
- Ministry of Science and Technology [MOST 111-2314-B075-036-MY3, MOST 111-2320-B-075-007]
- Taipei Veterans General Hospital [V111C-209, V111B-025]
Human pluripotent stem cells (PSCs) have the potential to replace diseased or injured tissues and are widely used in regenerative medicine. Induced pluripotent stem cells (iPSCs) can differentiate into various cell types and are being explored for the treatment of retinal diseases. Further clinical trials are needed to assess the efficacy and adverse effects of iPSC-based therapies.
Human pluripotent stem cells (PSCs), including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), represent valuable cell sources to replace diseased or injured tissues in regenerative medicine. iPSCs exhibit the potential for indefinite self-renewal and differentiation into various cell types and can be reprogrammed from somatic tissue that can be easily obtained, paving the way for cell therapy, regenerative medicine, and personalized medicine. Cell therapies using various iPSC-derived cell types are now evolving rapidly for the treatment of clinical diseases, including Parkinson's disease, hematological diseases, cardiomyopathy, osteoarthritis, and retinal diseases. Since the first interventional clinical trial with autologous iPSC-derived retinal pigment epithelial cells (RPEs) for the treatment of age-related macular degeneration (AMD) was accomplished in Japan, several preclinical trials using iPSC suspensions or monolayers have been launched, or are ongoing or completed. The evolution and generation of human leukocyte antigen (HLA)-universal iPSCs may facilitate the clinical application of iPSC-based therapies. Thus, iPSCs hold great promise in the treatment of multiple retinal diseases. The efficacy and adverse effects of iPSC-based retinal therapies should be carefully assessed in ongoing and further clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据